Fiche publication
Date publication
mai 2020
Journal
Pharmaceutical research
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LEBEAU Luc
,
Dr REMY Jean-Serge
,
Pr PONS Françoise
Tous les auteurs :
Gaillard B, Remy JS, Pons F, Lebeau L
Lien Pubmed
Résumé
Hemolysis is a serious side effect of antitumor alkylphospholipids (APLs) that limits dose levels and is a constraint in their use in therapeutic regimen. Nine prodrugs of promising APLs (miltefosine, perifosine, and erufosine) were synthesized so as to decrease their membrane activity and improve their toxicity profile while preserving their antineoplastic potency.
Mots clés
alkylphospholipid, erufosine, hemolytic toxicity, miltefosine, perifosine, prodrug
Référence
Pharm. Res.. 2020 May 27;37(6):106
